Literature DB >> 2721325

Micronodular cirrhosis after thiabendazole.

M A Roy1, F W Nugent, H T Aretz.   

Abstract

Hepatotoxicity secondary to the administration of thiabendazole has been rare since this drug was produced in 1964. In 14 of 15 patients reported previously in the literature, severe intrahepatic cholestasis resolved within seven months of the onset of illness. A recent report documented the progression to cirrhosis in a 15th patient. We report the second case of a patient with intrahepatic cholestasis that developed after treatment with thiabendazole and progressed to severe micronodular cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2721325     DOI: 10.1007/BF01540282

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  7 in total

1.  [Intrahepatic cholestasis by thiabendazole treated with phenobarbital].

Authors:  M Feregrino Goyos; A Lifshitz Guinzberg; A Hernández Berumen; J Ramírez Degollado; L F Cervantes
Journal:  Prensa Med Mex       Date:  1976 May-Jun

2.  Progressive bile duct injury after thiabendazole administration.

Authors:  J C Manivel; J R Bloomer; D C Snover
Journal:  Gastroenterology       Date:  1987-08       Impact factor: 22.682

3.  Severe intrahepatic cholestasis due to thiabendazole.

Authors:  R Jalota; J W Freston
Journal:  Am J Trop Med Hyg       Date:  1974-07       Impact factor: 2.345

4.  Chromomycosis. Treatment with thiabendazole.

Authors:  M A Bayles
Journal:  Arch Dermatol       Date:  1971-11

5.  Thiabendazole for the treatment of trichinosis in humans.

Authors:  H H Hennekeuser; K Pabst; W Poeplau; W Gerok
Journal:  Tex Rep Biol Med       Date:  1969-11

6.  Intrahepatic cholestasis and sicca complex after thiabendazole. Report of a case and review of the literature.

Authors:  D Rex; L Lumeng; J Eble; L Rex
Journal:  Gastroenterology       Date:  1983-09       Impact factor: 22.682

7.  Sicca complex and cholangiostatic jaundice in two members of a family probably caused by thiabendazole.

Authors:  A I Fink; C J MacKay; S S Cutler
Journal:  Ophthalmology       Date:  1979-10       Impact factor: 12.079

  7 in total
  1 in total

1.  Thiabendazole inhibits ubiquinone reduction activity of mitochondrial respiratory complex II via a water molecule mediated binding feature.

Authors:  Qiangjun Zhou; Yujia Zhai; Jizhong Lou; Man Liu; Xiaoyun Pang; Fei Sun
Journal:  Protein Cell       Date:  2011-08-06       Impact factor: 14.870

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.